Immunotherapy of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 4, 2004, Pages 185-189

  Nitsch, Roger M ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Amyloid; Antibodies; Neurodegeneration; Vaccination

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANTIBODY; BETA AMYLOID ANTIBODY; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QS 21; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MENINGOENCEPHALITIS; NEUROTRANSMISSION; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SENILE PLAQUE; VACCINATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODY FORMATION; DEMENTIA; DISEASE PROGRESSION; HIPPOCAMPUS; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; SENILE PLAQUES; TIME FACTORS;

EID: 11344254770     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Knopman DS, Parisi JE, Salviati A, et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003;62:1087-1095.
2. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62:925-931.
3. Greeve I, Kretzschmar D, Beyn A, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899-3906.
4. Dudal S, Krzywkowski P, Paquette J, et al. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol Aging. 2004;25:861-871.
5. Lewis J, Dickson DW, Lin WL, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487-1491.
6. Götz J, Chen F, Van Dorpe J, et al. Abeta 42 fibrils induce the formation of neurofibrillary tangles in P301L tau transgenic mice. Science. 2001;293:1491-1495.
7. Stern EA, Bacskai BJ, Hickey GA, et al. Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci. 2004;24:4535-4540.
8. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271-276.
9. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-539.
10. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium. 2003;34:385-397.
11. Ferrari A, Hoemdli F, Baechi T, et al. Beta-amyloid induces PHF-like tau filaments in tissue culture. J Biol Chem. 2003;278:40162-40168.
12. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;31;39:409-421.
13. Oddo S, Billings L, Kesslak JP, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321-332.
14. Bennett DA, Schneider JA, Wilson RS, et al. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378-384.
15. Duyckaerts C, Dickson DW. Neuropathology in Alzheimer's disease. In: Dickson ed. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. Basel: ISN Neuropath Press, 2003:47-65.
16. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
17. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
18. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-919.
19. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982-985.
20. Mohajeri HM, Saini K, Schultz JG, et al. Passive immunization against β-amyloid peptide protects CNS neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem. 2002;277:33012-33017.
21. Lombardo JA, Stem EA, McLellan ME, et al. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci. 2003;23:10879-10883.
22. Wilcock DM, Rojiani A, Rosenthal A, et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144-6151.
23. Lemere CA, Beierschmitt A, Iglesias M, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol. 2004;165:283-297.
24. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron. 2003;38:547-554.
25. Gilman S, Koller M, Black RS, et al. Neuropsychological, CSF, and neuropathological effects of A-beta immunotherapy (AN 1792) of Alzheimer's disease in an interrupted trial [Abstract]. Neurobiol Aging. 2004;25S2:84.
26. Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8:1270-1275.
27. Nicoll JA, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003;9:448-452.
28. Ferrer I, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11-20.
29. Fox NC, Black RS, Gilman S, et al. Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurobiol Aging. 2004;25(suppl 2):84.